Plasma Patents (Class 424/530)
-
Publication number: 20120266260Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.Type: ApplicationFiled: May 26, 2010Publication date: October 18, 2012Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson
-
Publication number: 20120251609Abstract: A demineralized cancellous bone matrix comprising a cancellous bone matrix that has been demineralized is described herein. The demineralized cancellous bone matrix is rigid and has certain dimensions, including a certain length. Implants comprising at least one demineralized cancellous bone matrix are also described. Also disclosed are methods for treating bone having a void or defect in a patient using at least one demineralized cancellous bone matrix. In addition, methods of making a demineralized cancellous bone matrix are disclosed.Type: ApplicationFiled: March 29, 2011Publication date: October 4, 2012Inventors: Yen-Chen Huang, Moon Hae Sunwoo, Arthur A. Gertzman
-
Patent number: 8278046Abstract: The disclosure is related generally to methods for testing mammary fluid (including milk) to establish or confirm the identity of the donor of the mammary fluid. Such methods are useful in the milk-bank business to improve safety.Type: GrantFiled: April 5, 2011Date of Patent: October 2, 2012Assignee: Prolacta BioscienceInventors: Elena M. Medo, Martin L. Lee, David J. Rechtman
-
Patent number: 8258117Abstract: The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.Type: GrantFiled: October 8, 2010Date of Patent: September 4, 2012Assignee: Piramal Healthcare (Canada) LtdInventors: Caroline D. Hoemann, Michael D. Buschmann, Marc D. McKee
-
Publication number: 20120201896Abstract: The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.Type: ApplicationFiled: April 18, 2012Publication date: August 9, 2012Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Martha M. Murray, Michael F. Murray, Jennifer Marler
-
Publication number: 20120201897Abstract: The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration.Type: ApplicationFiled: November 17, 2009Publication date: August 9, 2012Applicant: SEWON CELLONTECH CO., LTD.Inventors: Hyun-Shin Park, Ji-Chul Yu, Ju-Hee Park, Jang-Hoon Kim, Hun Kim, Sae-Bom Lee, Jae-Deog Jang, Cheong-Ho Jang
-
Patent number: 8236355Abstract: The present invention relates to an agent having COX-2 inhibition activity. In particular the present invention relates to a COX-2 inhibitor separated from a mixture of denatured plasma and at least one metal, metal ion or metal salt thereof.Type: GrantFiled: April 27, 2007Date of Patent: August 7, 2012Assignee: Cambridge Scientific Pty Ltd.Inventor: Maria Maud L. Eijkenboom
-
Publication number: 20120195947Abstract: The invention encompasses nanoparticle assemblies and methods for preparing nanoparticle and compositions comprising such nanoparticles for use in topical or skin applications. The invention further encompasses methods of complexing various molecular and cellular entities to the nanoparticles using the resulting nanoparticles of the invention as delivery devices. The nanoparticles can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of a complexed agent in vivo, protecting a complexed agent against degradation, increasing skin penetration and retention of drugs, and enhancing the water solubility/dispersibility of a drug or other agent.Type: ApplicationFiled: February 24, 2012Publication date: August 2, 2012Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni, Satheesh K. Podaralla, Mohammed Alqahtani
-
Publication number: 20120177694Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: ApplicationFiled: July 6, 2011Publication date: July 12, 2012Inventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Publication number: 20120165939Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.Type: ApplicationFiled: December 30, 2011Publication date: June 28, 2012Applicant: DEPUY MITEK, INC.Inventors: Stephanie M. Kladakis, Joseph J. Hammer, Shetty Dhanuraj, Sridevi Dhanaraj, Mark Timmer
-
Publication number: 20120141593Abstract: The present invention provides methods for feeding older sows that beneficially reduce feed intake in older sows, yet improve pig survival and weaning weight of pigs from older sows.Type: ApplicationFiled: February 10, 2012Publication date: June 7, 2012Applicant: APC, Inc.Inventors: Joe David Crenshaw, Joy Campbell, Louis E. Russell
-
Publication number: 20120114760Abstract: Embodiments of the invention are directed to methods of treating a wound by administering a wound-healing composition and the wound-healing composition. The wound-healing composition has a purified platelet-removed platelet-rich plasma and a wound-healing component. The wound-healing component is a protein, a peptide, or combinations thereof. The methods of treatment utilize an amount of the wound-healing composition sufficient to treat a patient with a wound, which may occur by promoting an activity of cell migration, cell proliferation, and/or angiogenesis. Also disclosed are processes for preparing the wound-healing composition.Type: ApplicationFiled: November 8, 2011Publication date: May 10, 2012Inventor: James Gandy
-
Patent number: 8168229Abstract: A method of making a pliable, bioabsorbable hemostatic dressing wherein the dressing is composed of fibers with at least one molecular-scale coating, which upon first contact with blood and due to a large area of contact with blood per unit weight of active ingredients, initiates and accelerates the biochemical blood clotting cascade processes.Type: GrantFiled: September 27, 2006Date of Patent: May 1, 2012Assignee: LNK Chemsolutions, LLCInventors: Gustavo Larsen, Ruben Spretz
-
Publication number: 20120093936Abstract: The present invention relates to methods and compositions for use in the treatment of specific medical conditions. The compositions of the invention comprise blood serum preparations, such as activated blood serum preparations. The present invention also relates to the use of such blood serum preparations for the treatment of diseases and disorders associated with inflammation and/or undesirable activation of the immune system, such as paradentosis, abortus habitualis, colitis ulcerosa, polymyalgia rheumatica, whiplash-associated disorders, endometriosis, adeomyosis and unexplained infertility.Type: ApplicationFiled: April 7, 2010Publication date: April 19, 2012Applicant: VELIN-PHARMA A/SInventors: Svend Lindenberg, Flemming Velin
-
Publication number: 20120087988Abstract: Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system.Type: ApplicationFiled: October 12, 2011Publication date: April 12, 2012Inventor: Richard Gold
-
Publication number: 20120089084Abstract: A plasma coating device for treating a wound comprises a plasma chamber having: one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. An aerosol delivery system is operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.Type: ApplicationFiled: June 15, 2010Publication date: April 12, 2012Inventors: Joe O'Keeffe, Peter Dobbyn, John O'Donoghus, Liam O'Neil
-
Publication number: 20120087989Abstract: The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants.Type: ApplicationFiled: June 11, 2010Publication date: April 12, 2012Applicants: BANC DE SANG I TEIXITS, UNIVERSITAT AUTÒNOMA DE BARCELONAInventors: Juan Francisco Julian Ibanez, Jorge Navines Lopez, Joan Ramon Grifols Ronda
-
Publication number: 20120076750Abstract: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.Type: ApplicationFiled: December 7, 2011Publication date: March 29, 2012Inventors: Hillary Enyart, Jacy Hoeppner, Mike Leach, Shon Steger, Sona Sundaramurthy
-
Publication number: 20120052012Abstract: The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting thermogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment.Type: ApplicationFiled: August 26, 2011Publication date: March 1, 2012Applicant: OLIGO MEDIC INC.Inventors: Abdellatif CHENITE, Amine SELMANI
-
Publication number: 20120045518Abstract: Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).Type: ApplicationFiled: March 5, 2010Publication date: February 23, 2012Applicant: THE UAB RESEARCH FOUNDATIONInventors: Vance G. Nielsen, James F. George, James K. Kirklin
-
Publication number: 20120034277Abstract: A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.Type: ApplicationFiled: October 12, 2011Publication date: February 9, 2012Inventor: Cuthbert O. SIMPKINS
-
Publication number: 20120027867Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Applicant: ENTEGRION, INC.Inventors: Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
-
Patent number: 8092837Abstract: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.Type: GrantFiled: April 27, 2007Date of Patent: January 10, 2012Assignee: Biomet Manufacturing CorpInventors: Hillary Enyart, Jacy Hoeppner, Mike Leach, Shon Steger, Sona Sundaramurthy
-
Publication number: 20120003324Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: ApplicationFiled: July 6, 2011Publication date: January 5, 2012Inventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Publication number: 20120003193Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: ApplicationFiled: July 6, 2011Publication date: January 5, 2012Inventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Publication number: 20120003279Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.Type: ApplicationFiled: July 6, 2011Publication date: January 5, 2012Inventors: Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
-
Patent number: 8071727Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8071728Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8071724Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8071725Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8071726Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: December 6, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 8067543Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 20, 2011Date of Patent: November 29, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20110280952Abstract: The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.Type: ApplicationFiled: May 31, 2011Publication date: November 17, 2011Applicants: BIOMED DEVICE S.R.L., UNIVERSITA' DEGLI STUDI DI PAVIAInventors: Carla Marcella Caramella, Maria Cristina Bonferoni, Silvia Stefania Rossi, Giuseppina Sandri, Franca Ferrari, Cesare Giuseppe Perotti, Claudia Del Fante
-
Patent number: 8053561Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.Type: GrantFiled: March 8, 2010Date of Patent: November 8, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
-
Patent number: 8038991Abstract: Embodiments of single component bioscaffolding systems formed of a hydrogel such as hyaluronic acid or salt thereof are described. The hyaluronic acid or salt thereof may be dissolved in a buffer, plasma, or combination thereof to minimize adverse immunogenic responses when applied to a treatment site. Additionally, the hydrogel component includes stem cells to facilitate angiogenesis or facilitate tissue repair and/or regeneration of ischemic tissue, particularly in compromised cardiac tissue. The bioscaffolding may also be formed on a stent or a cardiac medical device.Type: GrantFiled: November 1, 2007Date of Patent: October 18, 2011Assignee: Abbott Cardiovascular Systems Inc.Inventors: John J. Stankus, Eugene Michal, Mikael Trollsas, Brandon Katz, Shubhayu Basu
-
Publication number: 20110229499Abstract: A method for treating or preventing hemorrhagic shock comprising administering a composition comprising stem cells or a soluble factor produced by stem cells, such as stem cell factor (SCF) to a subject. For example, stem cells for use according to the invention can express elevated levels of an anti-apoptotic protein.Type: ApplicationFiled: March 10, 2011Publication date: September 22, 2011Inventors: Ed W. Childs, W. Roy Smythe
-
Patent number: 8017157Abstract: The present invention relates to a pharmaceutical composition for the treatment of wounds containing blood plasma or serum and a method for treating wounds effectively by applying said composition to the wound site to normalize the tissue-environment around the site.Type: GrantFiled: December 12, 2006Date of Patent: September 13, 2011Assignee: Osiris Therapeutics, Inc.Inventors: Won Min Yoo, Kyung Hee Chang, Nae Choon Yoo, Ki Chang Keum, Sang Yup Lee, Gene Lee
-
Patent number: 8003760Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: August 23, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 7985839Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: July 26, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 7985838Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: July 26, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20110177107Abstract: Methods of predicting the immunogenicity of a therapeutic protein in a subject are provided and the use of this method in selecting a protein for replacement therapy having the fewest immunogenic epitopes. The method is demonstrated by reference to ADAMTS13. Isolated allelic variants of ADAMTS13 that contribute to the variability in risk for both arterial and venous thrombotic disease development are provided. The allelic variants are identified as single nucleotide polymorphisms (ns-SNPs) in the ADAMTS13 gene, which result in haplotypes identified as H1 to H14. A method for improving outcomes of transfusions/transplant products is also provided by selection of haplotype matched therapeutics.Type: ApplicationFiled: January 14, 2011Publication date: July 21, 2011Inventor: Tommy Eugene Howard
-
Patent number: 7982010Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: January 8, 2010Date of Patent: July 19, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20110171207Abstract: Compositions containing soluble B7-H4 (sH4) antagonists in an amount effective to reduce, inhibit, or mitigate an inflammatory response in an individual and methods for the treatment or prophylaxis of inflammatory disorders and autoimmune diseases or disorders are provided. Soluble H4 has been discovered to interfere with B7-H4 activity including B7-H4's activity as an inhibitor of T cell immunity. Thus, interference of sH4 biological activity is an effective method to restore B7-H4 activity and thereby provide an effective method for treating inflammatory diseases or disorders including autoimmune diseases or disorders.Type: ApplicationFiled: March 23, 2011Publication date: July 14, 2011Inventor: Lieping Chen
-
Publication number: 20110142885Abstract: The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma powder, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder.Type: ApplicationFiled: September 16, 2010Publication date: June 16, 2011Inventors: Michael Haley, Dennis Hubbard, JR., Keith Rosiello
-
Publication number: 20110125089Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.Type: ApplicationFiled: March 26, 2009Publication date: May 26, 2011Applicant: ZYMOGENETICS, INC.Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcoa, Paul D. Bishop, Gerald W. Lasser
-
Publication number: 20110111049Abstract: The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery.Type: ApplicationFiled: April 11, 2008Publication date: May 12, 2011Inventors: Matthew T Andrews, Lester R. Drewes, Greg Beilman
-
Publication number: 20110104298Abstract: A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized in that four to eight parts of blood or blood plasma from donors having the blood group A, more than three parts to seven parts of blood or blood plasma from donors having the blood group B, zero to two parts of blood or blood plasma from donors having the blood group AB.Type: ApplicationFiled: August 24, 2010Publication date: May 5, 2011Inventors: Andrea Heger, Jürgen Römisch, Tor-Einar Svae, Wolfgang Marguerre
-
Patent number: 7931919Abstract: The invention is directed to stabilized whole-cell plasma, which retains the integrity and overall stability of the proteins and other macromolecules of the plasma. Stabilization is accomplished by the addition of glycine to plasma which allows for stabilization prior to freeze drying. Glycine, in the presence of the salt concentration in the plasma, does not recrystallize and acts as a superior stabilizer for the lyophilized plasma. The stability of the freeze dried plasma may be further improved by addition of protectants including calcium chloride, trisodium citrate, hydroxyethyl starch, ammonium sulfate and citric acid to maintain physiologic pH. Superior stability for a wide variety of plasma proteins and functions is shown. A system for the large scale preparation of sterile lyophilized plasma is also provided.Type: GrantFiled: August 14, 2006Date of Patent: April 26, 2011Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Irina B. Bakaltcheva, Lloyd Ketchum
-
Patent number: 7906149Abstract: A method for treating oleoresin induced allergic dermatitis by topically contacting an affected area with a therapeutically effective amount of one or more biopolymers for a sufficient amount of time to enable the one or more biopolymers to have an effect and removing the one or more biopolymers from the affected area. The oleoresin can be urushiol, isosolenopsin A, or a combination thereof. The one or more biopolymer can be albumin. The one or more biopolymers can provide a localized anti-inflammatory effect.Type: GrantFiled: May 25, 2007Date of Patent: March 15, 2011Assignee: Boval Company, L.P.Inventor: Cody L. Yarborough
-
Publication number: 20110033554Abstract: The invention relates to a novel method of virally inactivating biological fluids by solvent/detergent treatment of the fluid, followed by oil extraction and filtration.Type: ApplicationFiled: March 25, 2009Publication date: February 10, 2011Applicant: Research Foundation For Medical DevicesInventors: Thierry Burnouf, Magdy El-Ekiaby, Hadi Alphonse Goubran, Miryana Radosevich